BibTex RIS Kaynak Göster

Hepatitis B and C Seroprevalence in Leprosy Patients

Yıl 2015, Cilt: 5 Sayı: 3, 114 - 118, 06.02.2016
https://doi.org/10.5799/ahinjs.02.2015.03.0188

Öz

Objective: Leprosy is a contagious chronic granulomatous disease and commonly affects the eyes and the internal organs. Leprosy can be classified according to the level of immune response. Leprosy is a disease that is associated with defects in cellular immunity. This is why we have investigated the leprosy patients that were referred to our hospital for chronic hepatitis B and C co-infections. Methods: Fifty patients who were treated in the leprosy unit of Elazığ Research and Training hospital between the dates of June-December 2011 were enrolled to this descriptive study. Macro ELISA assay was performed for Hepatitis B,C and HIV.

Results: Fifty patients who were treated in the leprosy unit of our hospital participated in the study. A total of 8% HBsAg presence was noted. A total of 16 Anti HCV presence was noted in the patient group. Anti HCV positivity was determined at seven of 14 patients with tuberculoid form leprosy (50%) and nine of 33 lepromatous leprosy form (27,2%).

Conclusion: In conclusion, leprosy patients, especially lepromatous leprosy group, are immunologically vulnerable to HBV and HCV co-infections. Thus, physicians should be aware of HBV coinfections in these patients and education should be given to patients to increase their knowledge regarding risky situations for transmission of the disease. J Microbiol Infect Dis 2015;5(3): 114-118

Key words: Leprosy, Cellulary Immunity, Seroprevalance, Hepatitis B, Hepatitis C

Kaynakça

  • Altıparmak E., Koçak M., Kundakçı N. et al. Prevalance of hepatitis
  • B and hepatitis C infection in Leprosy patients. Turkish J Gastroenterology 1999; 10 (3):253-255.
  • Chimenos KE, Pascual CM, Pinol DC, Vinals IH, Rodríguez de
  • RCME, López LJ. Lepromatous leprosy: a review and case report. Med Oral Patol Oral Cir Bucal 2006; 11 (6):474-479.
  • World Health Organization. Weekly epidemiological record,
  • World Health Organization, 2011 (86);389-400.
  • Turkey Directorate of Public Health. Leprosy (Hanseniyazis)
  • http://www.thsm.gov.tr/upload/files/Lepra. (Turkish)
  • Pungpapong S, Kim WR, Poterucha JJ. Natural history of
  • hepatitis B virus infection: an update for clinicians. Mayo Clin
  • Proc 2007; 82:967-75.
  • European Centre for Disease Prevention and Control (ECDC).
  • Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. September 2010. http://ecdc.europa.eu/en/publications/Publications/
  • TER_100914_Hep_B_C%20_EU_neighbourhood.pdf 7. Tosun S. Hepatitis B vaccination and hepatitis vaccination results in our country, “Tabak F, Tosun S (eds). Viral Hepatitis”.Viral Hepatitis Prevention Society Publication, İstanbul Medical Press, İstanbul, 2013:413-439. (Turkish)
  • Gülaçtı U,Üstün C, Arlıer R, Turan M. The Seroprevalence of Hepatitis B and C among Healthcare Persons in Elazig Harput State Hospital. Konuralp Med J 2013; 5 (3):5-8.(Turkish).
  • Tözün N, Özdoğan O, Çakaloğlu Y, et al. A nationwide prevalence
  • Sstudy and risk factors for hepatitis A, B, C and D infections in Turkey. The 61st Annual Meeting of AASLD: The Liver Meeting® 2010. October 29 November 2 2010, Boston USA, Poster No: 789, Hepatology 2010; 52:1-697A. http://www.tasl.org.tr/files/file/tasl.
  • Balık İ, Tosun S, Tabak F, et al. Investigate the epidemiology
  • of viral hepatitis with mobile team to in our country. (VHSD Bus Project), XI. Ulusal Viral Hepatitis congress, s.44, PS01-10, Antalya (2012).(Turkish).
  • Ganem D, Prince AM. Hepatitis B virus infection – natural
  • history and clinical consequences. N Engl J Med 2004;350:1118-1129.
  • European Association for the Study of the Liver. EASL Clinical
  • Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
  • Rosa H, Costa AP, Ferraz ML, et al. Association between leprosy and hepatitis B infection. A survey in Goiania, central Brazil. Rev Inst Med Trop Sao Paulo 1992; 34:421-426.
  • Motta AC, Pereira KJ, Tarquínio DC, Vieira MB, Miyake K,Foss NT. Leprosy reactions: co-infections as a possible risk factor. Clinics (Sao Paulo) 2012; 67 (10):1145-1148.
  • Leitão C, Ueda D, de Moraes Braga AC, Boldt AB, MessiasReason
  • IJ. Leprosy and hepatitis B coinfection in southern Brazil. Braz J Infect Dis 2014; 18(1):8-12.
  • Ramos JM, Costa e Silva ÁM, Martins RM, et al. Prevalence of hepatitis B and C virus infection among leprosy patients in a leprosy-endemic region of central Brazil. Mem Inst Oswaldo Cruz 2011; 106:632-634.
  • Yvonnet B, Vincelot P, Millan J, et al. Hepatitis B virus infection
  • in lepromatous and tuberculoid patients from Senegal.Acta Leprol 1989; 7:63–6.
  • Rego VP, Machado PR, Martins I, Trindade R, Paraná R.Type 1 reaction in leprosy: characteristics and association with hepatitis B and C viruses. Rev Soc Bras Med Trop 2007;40: 546-549.
  • Nigam PK, Gupta GB, Khare A. Hepatic involvement and
  • hepatitis B surface antigen (Hbs Ag) in leprosy. Indian J Dermatol
  • Venereol Leprol 2003; 69 (1):32-4.
  • Machado PR, Johnson WD, Glesby MJ. The role of human
  • T cell lymphotrophic virus type 1, hepatitis B virus and hepatitis
  • C virus coinfections in leprosy. Mem Inst Oswaldo Cruz2012; 107 (1):43-8.
  • de Moraes Braga AC, Reason IJ, Maluf EC, Vieira ER. Leprosy
  • and confinement due to leprosy show high association with hepatitis C in Southern Brazil. Acta Trop 2006; 97(1):88-93.

-

Yıl 2015, Cilt: 5 Sayı: 3, 114 - 118, 06.02.2016
https://doi.org/10.5799/ahinjs.02.2015.03.0188

Öz

Amaç: Lepra bulaşıcı kronik granülomatöz bir hastalıktır ve sıklıkla göz ve iç organları etkilemektedir. Lepra immün yanıtın derecesine göre sınıflandırılabilir. Bu hastalık, hücresel immünite defekti ile ilgili bir hastalıktır. Bu nedenle, hastanemizde takip edilen lepra hastalarında kronik hepatit B ve C koenfeksiyonlarını inceledik. Yöntemler: Elazığ Eğitim ve Araştırma Hastanesi Lepra Ünitesi’nde Haziran ve Aralık 2011 yılları arasında tedavi olan elli hasta bu çalışma için değerlendirmeye alındı. Hepatit B ve Hepatit C antijen ve antikorlarının saptanması için Macro ELISA testi kullanıldı.Bulgular: Hastanemiz Lepra ünitesinde bulunan elli hasta çalışmaya alındı. HBsAg pozitifliği 8% oranında saptandı. On altı hastada anti HCV pozitifliği saptandı. Anti HCV pozitifliğinin tüberküloid lepra formunda olan 14 hastanın 7’sinde (%50) ve lepromatöz lepra formunda olan 33 hastanın 9’unda (%27.2) olduğu gözlendi. Sonuç: Sonuç olarak; özellikle lepramatöz lepra formunda olan lepra hastaları immünolojik olarak Hepatit B ve Hepatit C koenfeksiyonlarına duyarlıdır. Bu nedenle; klinisyen bu tür hastalarda koenfeksiyonlar açısından dikkatli olmalıdır ve hastalara, bu hastalığın bulaşmasında rol alan riskli davranışlara ilişkin eğitim verilerek bilgi düzeyleri artırılmalıdır

Kaynakça

  • Altıparmak E., Koçak M., Kundakçı N. et al. Prevalance of hepatitis
  • B and hepatitis C infection in Leprosy patients. Turkish J Gastroenterology 1999; 10 (3):253-255.
  • Chimenos KE, Pascual CM, Pinol DC, Vinals IH, Rodríguez de
  • RCME, López LJ. Lepromatous leprosy: a review and case report. Med Oral Patol Oral Cir Bucal 2006; 11 (6):474-479.
  • World Health Organization. Weekly epidemiological record,
  • World Health Organization, 2011 (86);389-400.
  • Turkey Directorate of Public Health. Leprosy (Hanseniyazis)
  • http://www.thsm.gov.tr/upload/files/Lepra. (Turkish)
  • Pungpapong S, Kim WR, Poterucha JJ. Natural history of
  • hepatitis B virus infection: an update for clinicians. Mayo Clin
  • Proc 2007; 82:967-75.
  • European Centre for Disease Prevention and Control (ECDC).
  • Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. September 2010. http://ecdc.europa.eu/en/publications/Publications/
  • TER_100914_Hep_B_C%20_EU_neighbourhood.pdf 7. Tosun S. Hepatitis B vaccination and hepatitis vaccination results in our country, “Tabak F, Tosun S (eds). Viral Hepatitis”.Viral Hepatitis Prevention Society Publication, İstanbul Medical Press, İstanbul, 2013:413-439. (Turkish)
  • Gülaçtı U,Üstün C, Arlıer R, Turan M. The Seroprevalence of Hepatitis B and C among Healthcare Persons in Elazig Harput State Hospital. Konuralp Med J 2013; 5 (3):5-8.(Turkish).
  • Tözün N, Özdoğan O, Çakaloğlu Y, et al. A nationwide prevalence
  • Sstudy and risk factors for hepatitis A, B, C and D infections in Turkey. The 61st Annual Meeting of AASLD: The Liver Meeting® 2010. October 29 November 2 2010, Boston USA, Poster No: 789, Hepatology 2010; 52:1-697A. http://www.tasl.org.tr/files/file/tasl.
  • Balık İ, Tosun S, Tabak F, et al. Investigate the epidemiology
  • of viral hepatitis with mobile team to in our country. (VHSD Bus Project), XI. Ulusal Viral Hepatitis congress, s.44, PS01-10, Antalya (2012).(Turkish).
  • Ganem D, Prince AM. Hepatitis B virus infection – natural
  • history and clinical consequences. N Engl J Med 2004;350:1118-1129.
  • European Association for the Study of the Liver. EASL Clinical
  • Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
  • Rosa H, Costa AP, Ferraz ML, et al. Association between leprosy and hepatitis B infection. A survey in Goiania, central Brazil. Rev Inst Med Trop Sao Paulo 1992; 34:421-426.
  • Motta AC, Pereira KJ, Tarquínio DC, Vieira MB, Miyake K,Foss NT. Leprosy reactions: co-infections as a possible risk factor. Clinics (Sao Paulo) 2012; 67 (10):1145-1148.
  • Leitão C, Ueda D, de Moraes Braga AC, Boldt AB, MessiasReason
  • IJ. Leprosy and hepatitis B coinfection in southern Brazil. Braz J Infect Dis 2014; 18(1):8-12.
  • Ramos JM, Costa e Silva ÁM, Martins RM, et al. Prevalence of hepatitis B and C virus infection among leprosy patients in a leprosy-endemic region of central Brazil. Mem Inst Oswaldo Cruz 2011; 106:632-634.
  • Yvonnet B, Vincelot P, Millan J, et al. Hepatitis B virus infection
  • in lepromatous and tuberculoid patients from Senegal.Acta Leprol 1989; 7:63–6.
  • Rego VP, Machado PR, Martins I, Trindade R, Paraná R.Type 1 reaction in leprosy: characteristics and association with hepatitis B and C viruses. Rev Soc Bras Med Trop 2007;40: 546-549.
  • Nigam PK, Gupta GB, Khare A. Hepatic involvement and
  • hepatitis B surface antigen (Hbs Ag) in leprosy. Indian J Dermatol
  • Venereol Leprol 2003; 69 (1):32-4.
  • Machado PR, Johnson WD, Glesby MJ. The role of human
  • T cell lymphotrophic virus type 1, hepatitis B virus and hepatitis
  • C virus coinfections in leprosy. Mem Inst Oswaldo Cruz2012; 107 (1):43-8.
  • de Moraes Braga AC, Reason IJ, Maluf EC, Vieira ER. Leprosy
  • and confinement due to leprosy show high association with hepatitis C in Southern Brazil. Acta Trop 2006; 97(1):88-93.
Toplam 39 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Kısa Rapor
Yazarlar

Türkkan Kaygusuz Bu kişi benim

Müge Özgüler

Leyla Güngör Bu kişi benim

Çiğdem Papila Bu kişi benim

Yayımlanma Tarihi 6 Şubat 2016
Yayımlandığı Sayı Yıl 2015 Cilt: 5 Sayı: 3

Kaynak Göster

APA Kaygusuz, T., Özgüler, M., Güngör, L., Papila, Ç. (2016). Hepatitis B and C Seroprevalence in Leprosy Patients. Journal of Microbiology and Infectious Diseases, 5(3), 114-118. https://doi.org/10.5799/ahinjs.02.2015.03.0188
AMA Kaygusuz T, Özgüler M, Güngör L, Papila Ç. Hepatitis B and C Seroprevalence in Leprosy Patients. J Microbil Infect Dis. Şubat 2016;5(3):114-118. doi:10.5799/ahinjs.02.2015.03.0188
Chicago Kaygusuz, Türkkan, Müge Özgüler, Leyla Güngör, ve Çiğdem Papila. “Hepatitis B and C Seroprevalence in Leprosy Patients”. Journal of Microbiology and Infectious Diseases 5, sy. 3 (Şubat 2016): 114-18. https://doi.org/10.5799/ahinjs.02.2015.03.0188.
EndNote Kaygusuz T, Özgüler M, Güngör L, Papila Ç (01 Şubat 2016) Hepatitis B and C Seroprevalence in Leprosy Patients. Journal of Microbiology and Infectious Diseases 5 3 114–118.
IEEE T. Kaygusuz, M. Özgüler, L. Güngör, ve Ç. Papila, “Hepatitis B and C Seroprevalence in Leprosy Patients”, J Microbil Infect Dis, c. 5, sy. 3, ss. 114–118, 2016, doi: 10.5799/ahinjs.02.2015.03.0188.
ISNAD Kaygusuz, Türkkan vd. “Hepatitis B and C Seroprevalence in Leprosy Patients”. Journal of Microbiology and Infectious Diseases 5/3 (Şubat 2016), 114-118. https://doi.org/10.5799/ahinjs.02.2015.03.0188.
JAMA Kaygusuz T, Özgüler M, Güngör L, Papila Ç. Hepatitis B and C Seroprevalence in Leprosy Patients. J Microbil Infect Dis. 2016;5:114–118.
MLA Kaygusuz, Türkkan vd. “Hepatitis B and C Seroprevalence in Leprosy Patients”. Journal of Microbiology and Infectious Diseases, c. 5, sy. 3, 2016, ss. 114-8, doi:10.5799/ahinjs.02.2015.03.0188.
Vancouver Kaygusuz T, Özgüler M, Güngör L, Papila Ç. Hepatitis B and C Seroprevalence in Leprosy Patients. J Microbil Infect Dis. 2016;5(3):114-8.